Stock listing
Lang & Schwarz:A41BQ3 Cellectar Biosciences, Inc. Aktie
German listing (Lang & Schwarz) of Cellectar Biosciences, Inc. · home listing NASDAQ:CLRB
Follow Cellectar Biosciences, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CLRB
$0.797 USD -0.088 (-10.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CLRB
- Day range
- $0.760 – $0.903 USDNov 20, 2026
- Volume
- 80,371 sharesNov 20, 2026
- Market cap
- $8.00M USDAt the close on Nov 20, 2026 · price × 10.04M shares outstanding
- 52-week range
- $0.760 – $4.700 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $143,250 USDMedian day 66,544 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CLRB · Home | $0.797 USD | -0.088 (-10.0%) | 80,371 | $0.903 | $0.903 | $0.760 | $0.885 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CLRB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.797 | -0.088 | -10.0% | $0.903 | $0.903 | $0.760 | 80,371 | |
| $0.885 | -0.035 | -3.8% | $0.920 | $0.920 | $0.880 | 50,165 | |
| $0.920 | -0.090 | -8.9% | $1.010 | $1.078 | $0.897 | 77,381 | |
| $1.010 | -0.130 | -11.4% | $1.130 | $1.140 | $1.000 | 126,562 | |
| $1.140 | -0.020 | -1.7% | $1.190 | $1.205 | $1.130 | 19,455 | |
| $1.160 | -0.050 | -4.1% | $1.210 | $1.220 | $1.150 | 50,906 | |
| $1.210 | -0.010 | -0.8% | $1.260 | $1.300 | $1.190 | 21,468 | |
| $1.220 | -0.060 | -4.7% | $1.300 | $1.315 | $1.220 | 63,370 | |
| $1.280 | +0.030 | +2.4% | $1.300 | $1.310 | $1.260 | 128,077 | |
| $1.250 | +0.100 | +8.7% | $1.130 | $1.276 | $1.125 | 76,951 | |
| $1.150 | -0.080 | -6.5% | $1.210 | $1.270 | $1.110 | 143,757 | |
| $1.230 | -0.080 | -6.1% | $1.280 | $1.370 | $1.230 | 87,792 | |
| $1.310 | +0.090 | +7.4% | $1.240 | $1.310 | $1.227 | 139,891 | |
| $1.220 | +0.015 | +1.2% | $1.230 | $1.255 | $1.180 | 66,544 | |
| $1.205 | -0.015 | -1.2% | $1.205 | $1.205 | $1.180 | 55,282 | |
| $1.220 | -0.020 | -1.6% | $1.220 | $1.260 | $1.190 | 111,805 | |
| $1.240 | +0.030 | +2.5% | $1.220 | $1.260 | $1.200 | 58,537 | |
| $1.210 | 0.000 | 0.0% | $1.230 | $1.290 | $1.160 | 161,564 | |
| $1.210 | -0.010 | -0.8% | $1.250 | $1.270 | $1.190 | 184,723 | |
| $1.220 | +0.050 | +4.3% | $1.190 | $1.220 | $1.140 | 58,227 | |
| $1.170 | -0.110 | -8.6% | $1.280 | $1.280 | $1.170 | 68,656 | |
| $1.280 | +0.050 | +4.1% | $1.250 | $1.330 | $1.230 | 134,955 | |
| $1.230 | +0.110 | +9.8% | $1.130 | $1.240 | $1.120 | 109,491 | |
| $1.120 | -0.020 | -1.8% | $1.180 | $1.200 | $1.120 | 195,300 | |
| $1.140 | -0.050 | -4.2% | $1.190 | $1.280 | $1.120 | 341,330 | |
| $1.190 | +0.010 | +0.8% | $1.210 | $1.270 | $1.150 | 382,262 | |
| $1.180 | -0.210 | -15.1% | $1.440 | $1.465 | $1.150 | 395,536 | |
| $1.390 | -0.040 | -2.8% | $1.550 | $1.600 | $1.360 | 539,388 | |
| $1.430 | -0.020 | -1.4% | $1.450 | $1.470 | $1.400 | 186,138 | |
| $1.450 | +0.050 | +3.6% | $1.410 | $1.490 | $1.370 | 91,480 | |
| $1.400 | -0.110 | -7.3% | $1.570 | $1.570 | $1.340 | 169,697 | |
| $1.510 | 0.000 | 0.0% | $1.550 | $1.620 | $1.470 | 42,570 | |
| $1.510 | -0.160 | -9.6% | $1.660 | $1.729 | $1.460 | 219,434 | |
| $1.670 | -0.110 | -6.2% | $1.790 | $1.790 | $1.670 | 60,681 | |
| $1.780 | -0.090 | -4.8% | $1.950 | $1.975 | $1.780 | 48,039 | |
| $1.870 | +0.030 | +1.6% | $1.870 | $1.870 | $1.820 | 30,182 | |
| $1.840 | +0.020 | +1.1% | $1.920 | $1.920 | $1.820 | 74,864 | |
| $1.820 | -0.010 | -0.5% | $1.980 | $1.980 | $1.806 | 86,034 | |
| $1.830 | +0.030 | +1.7% | $1.800 | $1.890 | $1.800 | 65,015 | |
| $1.800 | -0.275 | -13.3% | $2.070 | $2.090 | $1.800 | 124,577 | |
| $2.075 | -0.015 | -0.7% | $2.130 | $2.150 | $1.960 | 55,486 | |
| $2.090 | -0.140 | -6.3% | $2.250 | $2.309 | $2.060 | 72,943 | |
| $2.230 | -0.120 | -5.1% | $2.360 | $2.370 | $2.174 | 161,240 | |
| $2.350 | -0.030 | -1.3% | $2.370 | $2.420 | $2.350 | 50,009 | |
| $2.380 | -0.020 | -0.8% | $2.390 | $2.440 | $2.370 | 73,555 | |
| $2.400 | +0.050 | +2.1% | $2.370 | $2.440 | $2.370 | 71,669 | |
| $2.350 | +0.030 | +1.3% | $2.320 | $2.390 | $2.320 | 73,034 | |
| $2.320 | +0.010 | +0.4% | $2.310 | $2.340 | $2.280 | 33,372 | |
| $2.310 | 0.000 | 0.0% | $2.330 | $2.450 | $2.290 | 65,748 | |
| $2.310 | -0.060 | -2.5% | $2.350 | $2.400 | $2.310 | 38,394 | |
| $2.370 | +0.005 | +0.2% | $2.350 | $2.400 | $2.350 | 18,894 | |
| $2.365 | -0.045 | -1.9% | $2.410 | $2.450 | $2.350 | 44,376 | |
| $2.410 | +0.040 | +1.7% | $2.460 | $2.470 | $2.375 | 27,557 | |
| $2.370 | +0.020 | +0.9% | $2.330 | $2.400 | $2.330 | 26,575 | |
| $2.350 | -0.080 | -3.3% | $2.390 | $2.440 | $2.340 | 70,008 | |
| $2.430 | -0.030 | -1.2% | $2.460 | $2.500 | $2.420 | 48,766 | |
| $2.460 | -0.050 | -2.0% | $2.480 | $2.540 | $2.450 | 46,427 | |
| $2.510 | -0.020 | -0.8% | $2.520 | $2.550 | $2.490 | 17,294 | |
| $2.530 | -0.010 | -0.4% | $2.550 | $2.550 | $2.510 | 23,836 | |
| $2.540 | 0.000 | 0.0% | $2.570 | $2.570 | $2.520 | 10,321 | |
| $2.540 | 0.000 | 0.0% | $2.460 | $2.590 | $2.460 | 13,202 | |
| $2.540 | +0.020 | +0.8% | $2.590 | $2.600 | $2.500 | 16,671 | |
| $2.520 | -0.070 | -2.7% | $2.560 | $2.590 | $2.500 | 23,171 | |
| $2.590 | 0.000 | 0.0% | $2.600 | $2.600 | $2.500 | 26,653 | |
| $2.590 | -0.030 | -1.1% | $2.620 | $2.620 | $2.500 | 32,803 |
Splits
6 splits since 2011 · NASDAQ:CLRB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-153 | Consolidation |
- Ticker
- Lang & Schwarz:A41BQ3
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Latest earnings call · Nov 10, 2026
Cellectar Biosciences (NASDAQ:CLRB) Q3 2026 Earnings Call
Replay and transcript
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 41 slides
Latest news
Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Nov 10, 2026
Closed $1.22 (-4.7%) on Nov 10, 2026
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
Nov 4, 2026
Closed $1.23 (-6.1%) on Nov 4, 2026
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
Nov 2, 2026
Closed $1.22 (+1.2%) on Nov 2, 2026
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Oct 27, 2026
Closed $1.21 (0.0%) on Oct 27, 2026
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Oct 15, 2026
Closed $1.19 (+0.8%) on Oct 15, 2026
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Sep 29, 2026
Closed $1.82 (-0.5%) on Sep 29, 2026
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Aug 13, 2026
Closed $2.48 (-4.6%) on Aug 13, 2026
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
Jul 30, 2026
Closed $2.53 (+2.0%) on Jul 30, 2026
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Jul 15, 2026
Closed $2.61 (-0.8%) on Jul 15, 2026
Cellectar Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 164 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 13 calls with a replay · 13 with a transcript · latest Nov 10, 2026
- Decks
- 29 decks · latest October 2026
Where Cellectar Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CLRB · Home listing | NASDAQ | United States | USD |
| BOATS:CLRB | BOATS | United States | USD |
| gettex:NV40 | gettex | Germany | EUR |
| LS Exchange:A41BQ3 | LS Exchange | Germany | EUR |
| Frankfurt:NV40 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A41BQ3 · This page | Lang & Schwarz | Germany | EUR |
| Munich:NV40 | Munich | Germany | EUR |
Cash and shares
Aug 13, 2026 · Cellectar Biosciences — Investor Presentation (October 2026)
- Shares outstanding
- 9,452,108
- Fully diluted
- 61,804,329
Valuation
Price/book 0.4× against a median of 0.9×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$15.05M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.71
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. · NASDAQ:CLRB | US$8.00M | −US$15.05M | n/a | n/a | n/a | 0.4× | n/a | 0.1× | 1.71 |
| Brainstorm Cell Therapeutics Inc. · OTC:BCLI | US$8.31M | US$10.08M | n/a | n/a | n/a | n/a | n/a | n/a | 0.40 |
| Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTM | US$8.29M | −US$3.20M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.05 |
| Moleculin Biotech, Inc. · NASDAQ:MBRX | US$8.22M | US$1.04M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.42 |
| IN8bio, Inc. · NASDAQ:INAB | US$8.19M | −US$3.03M | n/a | n/a | n/a | 0.6× | n/a | 0.2× | 1.25 |
| Intensity Therapeutics, Inc. · NASDAQ:INTS | US$8.19M | −US$220,086 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.30 |
| Palatin Technologies, Inc. · AMEX:PTN | US$8.16M | US$4.58M | n/a | 12.7× | n/a | 4.0× | n/a | 0.1× | 0.61 |
| Dare Bioscience, Inc. · NASDAQ:DARE | US$8.01M | −US$2.65M | n/a | −1.9× | n/a | 3.4× | −749.8% | 0.4× | 1.34 |
| Immuron Limited · ASX:IMC | US$7.91M | US$1.94M | n/a | 0.4× | n/a | 1.1× | −49.8% | 0.0× | n/a |
| Phio Pharmaceuticals Corp. · NASDAQ:PHIO | US$7.84M | −US$2.77M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.24 |
| Vivesto AB · OMXSTO:VIVE | US$7.76M | US$6.12M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | n/a |
| Median of the others | US$8.17M | US$408,090 | 0.4× | 0.9× | −399.8% | 0.0× | 1.15 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.21 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| James Caruso | President, CEO and Director |
| Chad Kolean | Chief Financial Officer |
| Jarrod Longcor | Chief Operating Officer |
Board
| Director | Role |
|---|---|
| Douglas J. Swirsky | Chairman of the Board |
| Andrew Gu | Director |
| Asher Alban Chanan-Khan | Director |
| Frederick W. Driscoll | Director |
| James Caruso | President, CEO and Director |
| John Neis | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Cellectar Biosciences (NASDAQ:CLRB) Q3 2026 Earnings Call | Tue, Nov 10, 2026 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q1 2026 Earnings Call | Thu, May 14, 2026 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q4 2025 Earnings Call | Wed, Mar 04, 2026 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q1 2025 Earnings Call | Tue, May 13, 2025 · 8:30 PM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q4 2024 Earnings Call | Thu, Mar 13, 2025 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q3 2024 Earnings Call | Mon, Nov 18, 2024 · 8:00 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q2 2024 Earnings Call | Tue, Aug 13, 2024 · 8:30 AM ET | Replay |
All 13 calls
| Call | When | Status |
|---|---|---|
| Cellectar Biosciences (NASDAQ:CLRB) Q1 2024 Earnings Call | Tue, May 14, 2024 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q4 2023 Earnings Call | Wed, Mar 27, 2024 · 8:30 AM ET | Replay |
| Cellectar Biosciences (NASDAQ:CLRB) Q3 2023 Earnings Call | Thu, Nov 02, 2023 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −4.7% |
| Q2 2026 | Aug 13, 2026 · Before open | −4.6% |
| Q1 2026 | May 14, 2026 · Before open | +8.8% |
| Q4 2025 | Mar 4, 2026 | +3.4% |
| Q3 2025 | Nov 13, 2025 · Before open | −18.0% |
| Q2 2025 | Aug 14, 2025 · Before open | 0.0% |
| Q1 2025 | May 13, 2025 · Before open | −9.1% |
| Q4 2024 | Mar 25, 2025 · Before open | −1.1% |
| Q3 2024 | Nov 18, 2024 · Before open | −4.8% |
| Q2 2024 | Aug 13, 2024 | +7.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | +3.9% |
| Q4 2023 | Mar 27, 2024 · Before open | −5.6% |
| Q3 2023 | Nov 13, 2023 · Before open | +6.7% |
| Q2 2023 | Aug 14, 2023 · Before open | +1.9% |
| Q1 2023 | May 4, 2023 · Before open | −2.0% |
| Q4 2022 | Mar 9, 2023 · Before open | −10.5% |
| Q3 2022 | Nov 3, 2022 · Before open | −6.9% |
| Q2 2022 | Aug 5, 2022 · Before open | +3.5% |
| Q1 2022 | May 10, 2022 · Before open | −8.1% |
| Q4 2021 | Mar 21, 2022 · Before open | +15.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 41 slides | October 2026 |
| Investor Presentation (October 2026) | Investor deck | 39 slides | October 2026 |
| Investor Presentation (October 2026) | Investor deck | 38 slides | October 2026 |
| Q2 2026 Earnings Presentation | Earnings | 38 slides | Aug 13, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 49 slides | May 14, 2026 |
| Q1 2025 Earnings Presentation | Earnings | 41 slides | May 13, 2025 |
| Q1 2024 Earnings Presentation | Earnings | 7 slides | May 14, 2024 |
| Investor Presentation (March 2022) | Investor deck | 24 slides | Mar 15, 2022 |
| Investor Presentation (December 2020) | Investor deck | 31 slides | Dec 23, 2020 |
| IPO Roadshow (May 2020) | IPO roadshow | 34 slides | May 20, 2020 |
All 29 decks
Financings
| Raise | Date |
|---|---|
| Warrant exercise of common stock upon exercise of existing warrants Announced: about US$5.8M · US$5.25 a share · Warrants at US$6 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: Working capital and general corporate purposes, Phase 1b study of CLR 125 in triple-negative breast cancer, and preparing a Conditional Marketing Authorization filing with the EMA | Oct 7, 2025 |
| Public offering of class A Units and Class B Units Closed: US$6.9M raised · US$5 a unit · Warrants at US$5.25 for 60 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Insiders: The offering includes participation from executive management Use of proceeds: General corporate purposes, working capital and operating expenses, and a Phase 1b study of CLR 125 in triple-negative breast cancer | Jul 2, 2025 |
| Warrant exercise of common stock upon exercise of existing warrants Announced: about US$2.5M · US$0.3041 a share · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) Use of proceeds: General corporate purposes, including working capital and operating expenses | Jun 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 213.6K | 291.7K | 192.4K | 238.9K | 227.6K | 207.9K | 189.4K | 82.3K | 1.55M | 356.7K |
| Gross profit | -213.6K | -291.7K | -192.4K | -238.9K | -227.6K | -207.9K | -189.4K | -82.3K | -1.55M | -356.7K |
| Research and development | 11.5M | 26.1M | 27.3M | 18.3M | 17.6M | 10.1M | 9.00M | 6.84M | 9.47M | 4.75M |
| Selling, general and administrative | 11.5M | 25.6M | 11.7M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M |
| Operating income | -23.0M | -51.8M | -39.0M | -28.8M | -24.1M | -15.3M | -14.2M | -13.3M | -13.6M | -9.45M |
| Depreciation and amortization | 213.6K | 291.7K | 192.4K | 148.4K | 149.9K | 141.5K | 132.8K | 82.3K | 1.55M | 356.7K |
| EBITDA | -22.8M | -51.5M | -38.8M | -28.7M | -24.0M | -15.1M | -14.0M | -13.2M | -12.1M | -9.09M |
| Interest expense | 301.0K | 2.28K | 10.9K | 42.7K | 29.7K | 16.6K | 7.90K | |||
| Income before tax | -21.8M | -44.5M | -42.8M | -31.9M | -24.1M | -15.1M | -14.1M | -13.2M | -13.6M | -6.18M |
| Income tax | 66.0K | -60.0K | -60.0K | -152.2K | -337.6K | 0 | 0 | 0 | 0 | |
| Net income | -21.8M | -44.6M | -42.8M | -31.8M | -24.1M | -15.1M | -14.1M | -13.2M | -13.6M | -6.18M |
| Earnings per share, basic | -8.35 | -36.52 | -3.50 | -4.51 | -4.35 | -0.76 | -1.84 | -5.23 | -10.70 | -2.14 |
| Earnings per share, diluted | -8.35 | -41.89 | -3.50 | -4.51 | -4.35 | -1.84 | -1.84 | -5.23 | -10.70 | -2.14 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 13.2M | 23.3M | 9.56M | 19.9M | 35.7M | 57.2M | 10.6M | 13.3M | 10.0M | 11.4M |
| Short-term investments | 55.0K | 55.0K | 55.0K | |||||||
| Inventory | 0 | 0 | ||||||||
| Current assets | 14.0M | 24.3M | 10.5M | 20.5M | 36.6M | 57.9M | 11.4M | 14.0M | 10.5M | 12.2M |
| Property, plant and equipment | 549.4K | 757.1K | 1.09M | 418.6K | 344.5K | 356.0K | 435.1K | 543.3K | 244.7K | 1.44M |
| Goodwill | 0 | 0 | 1.68M | 1.68M | ||||||
| Total assets | 15.0M | 25.5M | 12.1M | 21.6M | 37.2M | 58.7M | 12.3M | 15.1M | 12.9M | 15.3M |
| Accounts payable | 1.44M | 4.11M | 5.62M | 2.56M | 1.42M | 1.43M | 1.28M | 612.0K | 933.0K | 1.42M |
| Current liabilities | 4.75M | 9.39M | 25.4M | 11.5M | 3.99M | 3.56M | 2.77M | 1.62M | 2.11M | 1.63M |
| Long-term debt | 2.00K | 0 | ||||||||
| Total debt | 409.6K | 494.0K | 553.0K | 603.8K | 301.7K | 421.6K | 527.5K | 2.21K | 5.25K | 94.6K |
| Total liabilities | 5.06M | 9.80M | 25.9M | 12.1M | 4.16M | 3.86M | 3.19M | 1.79M | 2.12M | 1.78M |
| Shareholders' equity | 8.54M | 14.3M | -15.2M | 8.15M | 29.1M | 54.8M | 9.06M | 13.3M | 10.8M | 13.5M |
| Shares outstanding | 4.24M | 1.54M | 20.7M | 9.39M | 6.11M | 45.4M | 9.39M | 4.73M | 1.67M | 10.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.1M | -47.6M | -32.4M | -25.2M | -22.6M | -13.9M | -11.7M | -11.4M | -11.0M | -8.28M |
| Capital spending | -5.88K | -104.2K | -864.0K | -226.0K | -141.4K | -62.4K | -24.5K | -385.0K | -346.7K | -72.3K |
| Free cash flow | -23.1M | -47.7M | -33.2M | -25.4M | -22.7M | -14.0M | -11.7M | -11.8M | -11.4M | -8.35M |
| Cash from investing | -5.88K | -104.2K | -864.0K | -226.0K | -141.4K | -62.4K | -24.5K | -330.0K | -346.7K | -72.3K |
| Cash from financing | 13.0M | 61.4M | 22.9M | 9.61M | 1.25M | 60.5M | 9.02M | 15.0M | 9.93M | 15.9M |
| Dividends paid | -2.24M | -1.45M | 0 | |||||||
| Share buybacks | 642.5K | 9.02M | 8.19M | 3.71M | -1 | |||||
| Change in cash | -10.1M | 13.7M | -10.3M | -15.8M | -21.5M | 46.6M | -2.70M | 3.25M | -1.44M | 7.59M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Aug 4, 2026 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jul 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 10, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 5, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 2, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 29, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 29, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | May 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 28, 2026 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | May 22, 2026 | Other filings | SEC |
| S-1 · Registration statement | May 19, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | May 18, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 18, 2026 | Management or board change | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 6, 2026 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Results | SEC |
| 10-K · Annual report | Mar 4, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 21, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| S-1 · Registration statement | Oct 20, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 10, 2025 | Results | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jul 2, 2025 | Other filings | SEC |
| 424B4 · Prospectus | Jul 1, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 30, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 30, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 30, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| S-1 · Registration statement | Jun 26, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 5, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | May 29, 2025 | Other filings | SEC |
| DRS · Draft registration statement | May 23, 2025 | Offer document | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 17, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 7, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 7, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 4, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 3, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 31, 2025 | Current report | SEC |
| S-1 · Registration statement | Jan 29, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 27, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| 8-K · Current report | Nov 18, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 18, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 15, 2024 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| NT 10-Q · Late filing notice | Nov 13, 2024 | Explanation request | SEC |
| 8-K · Current report | Nov 1, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Oct 29, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Oct 29, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Oct 29, 2024 | Annual report | SEC |
| 8-K · Current report | Aug 23, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 14, 2024 | Big-stake notice | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2024 | Explanation request | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Aug 9, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 24, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 23, 2024 | Results | SEC |
| CORRESP · Letter to the SEC | Jul 22, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 22, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 11, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 11, 2024 | Current report | SEC |
| 8-K · Current report | Jun 25, 2024 | Material contract | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | May 31, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 24, 2024 | Offer document | SEC |
| DEFR14A | May 16, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 25, 2024 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 1, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2024 | Results | SEC |
| 10-K · Annual report | Mar 27, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 31, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 25, 2024 | Current report | SEC |
| 8-K · Current report | Jan 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Dec 7, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Dec 5, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 29, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| EFFECT · Notice that a registration is effective | Oct 31, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Oct 30, 2023 | Offer document | SEC |
| 8-K · Current report | Oct 27, 2023 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Oct 26, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | Oct 25, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 12, 2023 | Other filings | SEC |
| S-3 · Registration statement | Oct 5, 2023 | Offer document | SEC |
| DEF 14A · Proxy statement | Oct 2, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 22, 2023 | Meeting notice | SEC |
| D | Sep 22, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2023 | Material contract | SEC |
| 8-K · Current report | Aug 21, 2023 | Current report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jun 29, 2023 | Current report | SEC |
| 8-K · Current report | Jun 29, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2023 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 20, 2023 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Jun 20, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 14, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jun 14, 2023 | Current report | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Cellectar Biosciences, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 10,039,183
- Fully diluted
- 10,039,183
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 10,039,183 | Nov 6, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$5.25 · expire about Jul 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 10,039,183 |
| Sep 30, 2026 | 10,039,183 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brian M. Posner Other companies: Stran & Company, Inc. (Independent Director · Since at least Jul 8, 2025); Firefly Neuroscience, Inc. (Director · Since at least Aug 12, 2024); electroCore, Inc. (Chief Financial Officer · Apr 1, 2019 – Jan 12, 2024 · Past); Ocean Power Technologies, Inc. (Chief Financial Officer · May 21, 2010 – Jul 16, 2013 · Past); Power Medical Interventions Inc (Chief Financial Officer · Jan 5, 2009 – Jan 15, 2009 · Past); Pharmacopeia Inc (EVP, CFO · Dec 30, 2005 – Dec 23, 2008 · Past) | Chief Financial Officer · Apr 1, 2018 – Jan 17, 2019 · Past |
| Stephen A Hill Other companies: Lipocine Inc. (Director · Jan 6, 2014 – Dec 16, 2020 · Past); Gyre Therapeutics, Inc. (Director · Dec 1, 2012 – Sep 6, 2018 · Past); ArQule Inc (President and CEO, Director · Jan 19, 2006 – Oct 4, 2007 · Past) | Director · Aug 14, 2014 – Jun 24, 2020 · Past |
| Charles Thomas Bernhardt III Other companies: Echo Therapeutics Inc (Interim CFO · Jul 16, 2014 – Jul 16, 2014 · Past); AIM ImmunoTech Inc. (Chief Financial Officer · Jan 1, 2009 – Dec 22, 2011 · Past) | Interim CFO · Mar 9, 2019 – Mar 9, 2019 · Past |
| Douglas J. Swirsky Other companies: MaxCyte, Inc. (CHIEF FINANCIAL OFFICER · Since at least Mar 15, 2024) | Director · Since at least Jun 14, 2024 |
| Frederick W. Driscoll Other companies: Lite Strategy, Inc. (Chairperson, Non-Executive Director · Since at least Jul 15, 2025) | Director · Since at least Jul 7, 2026 |
| James Caruso Other companies: Allos Therapeutics Inc (Chief Commercial Officer · Jun 5, 2006 – Mar 1, 2010 · Past) | President, CEO and Director · Since at least Jun 15, 2015 |
| John E Friend II Other companies: Kazia Therapeutics Ltd (Chief Executive Officer · Since at least Jan 8, 2026) | Chief Medical Officer · Apr 17, 2017 – Mar 4, 2021 · Past |
| Andrei Shustov | Senior Vice President, Medical · Feb 15, 2023 – Jun 14, 2024 · Past |
| Andrew Gu | Director · Since at least May 14, 2026 |
| Asher Alban Chanan-Khan | Director · Since at least Jun 23, 2021 |
All 18 people
| Person | Seat |
|---|---|
| Cameron Szakacs | VP of Clinical Development · Nov 24, 2014 – Nov 24, 2014 · Past |
| Chad Kolean | Chief Financial Officer · Since at least Aug 14, 2014 |
| Darrell Shane Lea | Chief Commercial Officer · Nov 21, 2022 – Jun 14, 2024 · Past |
| Igor D Grachev | Chief Medical Officer · Jan 6, 2020 – Jan 6, 2020 · Past |
| Jamey P Weichert | Chief Scientific Officer · Aug 14, 2014 – May 12, 2016 · Past |
| Jarrod Longcor | Chief Operating Officer · Since at least Jul 15, 2016 |
| John Neis | Director · Since at least Apr 20, 2016 |
| Stefan Loren | Director · Jun 14, 2024 – Feb 14, 2025 · Past |
Log in to ask 6ix AI your own questions about Cellectar Biosciences, Inc.